(ng/ml) | N | PFOA | PFDA |
---|
Crude OR (95% CI) | Adjusted OR (95% CI) | Crude OR (95% CI) | Adjusted OR (95% CI) |
---|
Control | 657 | Ref | Ref | Ref | Ref |
ER- | 96 | 1.01 (0.81, 1.26) | 1.08 (0.82, 1.41) | 0.93 (0.76, 1.14) | 0.94 (0.72, 1.22) |
ER + | 218 | 1.43 (1.22, 1.67)* | 1.47 (1.19, 1.80)* | 1.19 (1.01, 1.41)* | 1.21 (0.98, 1.50) |
PR- | 131 | 1.00 (0.82, 1.21) | 1.03 (0.81, 1.30) | 1.01 (0.84, 1.22) | 0.93 (0.73, 1.18) |
PR + | 183 | 1.42 (1.19, 1.68)* | 1.36 (1.09, 1.69)* | 1.06 (0.90, 1.26) | 1.04 (0.83, 1.30) |
Luminal A | 168 | 1.23 (1.03, 1.46)* | 1.36 (1.08, 1.71)* | 1.12 (0.94, 1.34) | 1.12 (0.89, 1.42) |
Luminal B | 52 | 1.03 (0.77, 1.38) | 1.06 (0.74, 1.50) | 0.84 (0.66, 1.07) | 0.83 (0.61, 1.13) |
HER2 | 65 | 1.46 (1.13, 1.90)* | 1.62 (1.19, 2.21)* | 1.28 (0.97, 1.70) | 1.26 (0.91, 1.76) |
Basal | 29 | 1.72 (1.20, 2.47)* | 1.45 (0.93, 2.24) | 1.20 (0.80, 1.80) | 1.06 (0.70, 1.60) |
- Note: According to the standard for molecular typing of breast cancer, cases were also identified as luminal A subtype, luminal B subtype, HER2 subtype, and basal-like subtypes. Final multivariable models adjusted for age at baseline (years), BMI (kg/m2), smoking history, age at menarche (years), age of menopause (years), parity, breastfeeding duration (months), use of estrogen or estrogen replacement therapy, family history of breast cancer, education (years), monthly household income per capita (RMB/month), red meat consumption, pickled, fried, smoked, and barbecued food consumption. The OR and 95% CI of breast cancer were estimated by one SD increase in ln-transformed PFOA and PFDA as continuous variables
- Abbreviations: OR Odds ratios; CI Confidence interval, PFOA Perfluorooctanoic acid, PFDA Perfluoro-n-decanoic acid, ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2
- * p-value for trend < 0.05